Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shuangyi Bai

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
Biorxiv : the Preprint Server for Biology|June 19, 2024
Antigen specificity shapes antibody functions in tuberculosisJoshua R Miles, Pei Lu, Shuangyi Bai, et al.
Cell Reports|December 10, 2025
ESAT-6 and CFP-10 reactive IgG in patients with tuberculosis inhibits intracellular bacteriaJoshua R Miles, Pei Lu, Shuangyi Bai, et al.
Iscience|October 13, 2025
A recombinant Cedar virus preclinical model that recapitulates neurological features of henipavirus diseaseCeleste Huaman, Caitlyn Clouse, Madeline Rader, et al.
Medrxiv : the Preprint Server for Health Sciences|October 27, 2022
Antibody-mediated protection against symptomatic COVID-19 can be achieved at low serum neutralizing titersPete Schmidt, Kristin Narayan, Yong Li, et al.
Research Square|June 5, 2026
Identification of a unique humoral immune signature of Sudan ebolavirus persistence in human survivorsBronwyn Gunn, Shuangyi Bai, Haruna Muwonge, et al.
Science Translational Medicine|March 22, 2023
Antibody-mediated protection against symptomatic COVID-19 can be achieved at low serum neutralizing titersPete Schmidt, Kristin Narayan, Yong Li, et al.
Immunity, Inflammation and Disease|December 11, 2024
Post-COVID immunity in patients with solid tumor or hematological malignancies treated with SARS-CoV-2 monoclonal antibodiesGilberto Sabino-Santos, Cathryn E Leggio, Sean M Litwin, et al.
Research Square|May 5, 2025
Severe long-term clinical sequelae among Sudan ebolavirus disease survivors 2 years post-infectionHaruna Muwonge, Carolyne Nasimiyu, Barnabas Bakamutumaho, et al.
BMC Medicine|July 18, 2025
Long-term clinical sequelae among Sudan ebolavirus disease survivors 2 years post-infection: a matched cohort studyHaruna Muwonge, Carolyne Nasimiyu, Barnabas Bakamutumaho, et al.
Frontiers in Immunology|August 18, 2025
Fc-modification of anti-PcrV gene-encoded antibodies modulates complement-mediated killing of Pseudomonas aeruginosaJillian Eisenhauer, Spencer Dublin, Jihae Choi, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Biorxiv : the Preprint Server for Biology|June 19, 2024
Antigen specificity shapes antibody functions in tuberculosisJoshua R Miles, Pei Lu, Shuangyi Bai, et al.
Cell Reports|December 10, 2025
ESAT-6 and CFP-10 reactive IgG in patients with tuberculosis inhibits intracellular bacteriaJoshua R Miles, Pei Lu, Shuangyi Bai, et al.
Iscience|October 13, 2025
A recombinant Cedar virus preclinical model that recapitulates neurological features of henipavirus diseaseCeleste Huaman, Caitlyn Clouse, Madeline Rader, et al.
Medrxiv : the Preprint Server for Health Sciences|October 27, 2022
Antibody-mediated protection against symptomatic COVID-19 can be achieved at low serum neutralizing titersPete Schmidt, Kristin Narayan, Yong Li, et al.
Research Square|June 5, 2026
Identification of a unique humoral immune signature of Sudan ebolavirus persistence in human survivorsBronwyn Gunn, Shuangyi Bai, Haruna Muwonge, et al.
Science Translational Medicine|March 22, 2023
Antibody-mediated protection against symptomatic COVID-19 can be achieved at low serum neutralizing titersPete Schmidt, Kristin Narayan, Yong Li, et al.
Immunity, Inflammation and Disease|December 11, 2024
Post-COVID immunity in patients with solid tumor or hematological malignancies treated with SARS-CoV-2 monoclonal antibodiesGilberto Sabino-Santos, Cathryn E Leggio, Sean M Litwin, et al.
Research Square|May 5, 2025
Severe long-term clinical sequelae among Sudan ebolavirus disease survivors 2 years post-infectionHaruna Muwonge, Carolyne Nasimiyu, Barnabas Bakamutumaho, et al.
BMC Medicine|July 18, 2025
Long-term clinical sequelae among Sudan ebolavirus disease survivors 2 years post-infection: a matched cohort studyHaruna Muwonge, Carolyne Nasimiyu, Barnabas Bakamutumaho, et al.
Frontiers in Immunology|August 18, 2025
Fc-modification of anti-PcrV gene-encoded antibodies modulates complement-mediated killing of Pseudomonas aeruginosaJillian Eisenhauer, Spencer Dublin, Jihae Choi, et al.
Pageof 3